Literature DB >> 33721040

Navigating the diverse immune landscapes of psoriatic arthritis.

Christopher Ritchlin1.   

Abstract

The goal of remission in psoriatic arthritis (PsA) has remained elusive despite the influx of a range of new therapies over the last 20 years. In contrast, therapeutic responses to agents that inhibit IL-23 or IL-17 have demonstrated impressive efficacy in psoriasis. In part, the divergent responses in these two disorders are likely related to the heterogeneity of tissue involvement in PsA and the interplay of multiple different cell populations and molecular pathways. In this narrative review, we will examine the plasticity of the immune response in PsA from the perspective of the Th17 cell and monocyte and discuss recent findings regarding the importance of CD8+ T resident cells in disease pathogenesis. We will then examine the effects of cytokines on epithelial cell and stromal populations and finally discuss new data regarding immune cell and tissue resident cell cross-talk in entheses and bone. Lastly, the potential therapeutic targets that have emerged from these investigations will be discussed.

Entities:  

Keywords:  Psoriasis; Psoriatic arthritis; Resident tissue cells; Therapeutics; Type 17 cell

Mesh:

Substances:

Year:  2021        PMID: 33721040     DOI: 10.1007/s00281-021-00848-x

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   11.759


  101 in total

1.  The IL-23-IL-17 axis in inflammatory arthritis.

Authors:  Erik Lubberts
Journal:  Nat Rev Rheumatol       Date:  2015-09-15       Impact factor: 20.543

Review 2.  Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines.

Authors:  Arthur F Kavanaugh; Christopher T Ritchlin
Journal:  J Rheumatol       Date:  2006-05-15       Impact factor: 4.666

Review 3.  Recognizing and managing comorbidities in psoriatic arthritis.

Authors:  Alexis Ogdie; Sergio Schwartzman; M Elaine Husni
Journal:  Curr Opin Rheumatol       Date:  2015-03       Impact factor: 5.006

Review 4.  Psoriatic Arthritis.

Authors:  Christopher T Ritchlin; Robert A Colbert; Dafna D Gladman
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

Review 5.  Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.

Authors:  Ellen M Gravallese; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2018-11       Impact factor: 20.543

Review 6.  A cellular and molecular view of T helper 17 cell plasticity in autoimmunity.

Authors:  Ralph Stadhouders; Erik Lubberts; Rudi W Hendriks
Journal:  J Autoimmun       Date:  2017-12-22       Impact factor: 7.094

Review 7.  Strategies to Improve Outcomes in Psoriatic Arthritis.

Authors:  Christopher Ritchlin; Jose U Scher
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

8.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

9.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.

Authors:  Daniel J Cua; Jonathan Sherlock; Yi Chen; Craig A Murphy; Barbara Joyce; Brian Seymour; Linda Lucian; Wayne To; Sylvia Kwan; Tatyana Churakova; Sandra Zurawski; Maria Wiekowski; Sergio A Lira; Daniel Gorman; Robert A Kastelein; Jonathon D Sedgwick
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

10.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

View more
  1 in total

1.  Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.

Authors:  Laure Gossec; Stefan Siebert; Paul Bergmans; Kurt de Vlam; Elisa Gremese; Beatríz Joven-Ibáñez; Tatiana V Korotaeva; Frederic Lavie; Wim Noël; Michael T Nurmohamed; Petros P Sfikakis; Elke Theander; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2022-02-24       Impact factor: 27.973

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.